Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
CML survey reveals patient TKI adherence, disease anxiety

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness. [More]
Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

Cord Blood America’s 2015 second quarter revenue increases 39.0% to $1.41 million

Cord Blood America, Inc. today announced financial results for the second quarter ended June 30, 2015. [More]
Newly developed big data technique may have significant impact on health care

Newly developed big data technique may have significant impact on health care

Rice University scientists have developed a big data technique that could have a significant impact on health care. The Rice lab of bioengineer Amina Qutub designed an algorithm called "progeny clustering" that is being used in a hospital study to identify which treatments should be given to children with leukemia. [More]
UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico. [More]
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis. [More]
Researchers create new cell screening method for immunotherapy cancer treatments

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful. [More]
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands. [More]
UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers. [More]
FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours. [More]
Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Acute lymphoblastic leukemia (ALL) leukemia is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells but also by their response to therapies. Now, an international team of scientists from Berlin, Düsseldorf, Hannover, Heidelberg, Kiel, and Zurich have succeeded in decoding the molecular characteristics of an as yet incurable subtype of leukemia, paving the way for new therapeutic approaches. [More]
Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells but also by their response to therapies. [More]
PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib). [More]
New tool combines drugs to target kinase dependency in cancer

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer. [More]
Researchers establish safety, dosing of new drug for treating blood cancers

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology. [More]
Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and Hannover has now succeeded in decoding a specific form of this leukemia, which is regarded as incurable, and in obtaining insights for new therapeutic possibilities. [More]
Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

Chronic myeloid leukaemia patients with rare BCR-ABL fusions may be missed by quantitative polymerase chain reaction, research suggests. [More]
New study reveals protein's critical role in development and progression of AML

New study reveals protein's critical role in development and progression of AML

A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Stem cell transplantation improves outcomes in children with rare form of chronic blood cancer

Stem cell transplantation improves outcomes in children with rare form of chronic blood cancer

Researchers in the Division of Hematology, Oncology and Blood & Marrow Transplantation at Children's Hospital Los Angeles have shown greatly improved outcomes in using stem cell transplantation to treat patients with a serious but very rare form of chronic blood cancer called juvenile myelomonocytic leukemia (JMML). [More]
Genetic variation influences survival in patients with multiple myeloma

Genetic variation influences survival in patients with multiple myeloma

As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it. [More]
Advertisement